前列腺原发性高级别尿路上皮癌伴18F-PSMA PET/CT阴性表现
本文报告一例81岁男性前列腺原发性高级别尿路上皮癌,增强MRI提示恶性病变但18F-PSMA PET/CT未见明显示踪剂摄取;术后免疫组化GATA3、CK7阳性而PSA、AR阴性确诊。提示PSMA PET/CT阴性可作为鉴别非腺癌性前列腺恶性肿瘤的重要诊断线索。
要点
- 前列腺原发尿路上皮癌可表现为18F-PSMA PET/CT阴性。
- MRI提示恶性而PSMA阴性时应考虑非腺癌性前列腺肿瘤。
- 免疫组化GATA3、CK7阳性及PSA、AR阴性有助确诊。
核心结论
- 18F-PSMA PET/CT阴性可能作为区分非腺癌性前列腺恶性肿瘤的重要诊断线索。
研究设计与样本
- 本文为病例报告,描述一例81岁男性前列腺原发性高级别尿路上皮癌的影像与病理表现。
主要发现
- 增强前列腺MRI最初提示恶性病变,但18F-PSMA PET/CT未见明显示踪剂摄取。
- 术后免疫组化显示尿路上皮标志物GATA3和CK7阳性,而前列腺特异标志物PSA和AR阴性。
关键数值与推荐
- 免疫组化GATA3和CK7阳性、PSA和AR阴性支持前列腺原发性高级别尿路上皮癌诊断。
临床怎么用
- 对前列腺MRI提示恶性而18F-PSMA PET/CT阴性的病例,应警惕非腺癌性前列腺恶性肿瘤并行免疫组化鉴别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This case report describes an 81-year-old man with primary high-grade urothelial carcinoma of the prostate, which presented with a negative 18 F-PSMA PET/CT. Contrast-enhanced prostate MRI initially suggested a malignant lesion; however, 18 F-PSMA PET/CT revealed no significant tracer uptake. Postoperative immunohistochemical analysis demonstrated positivity for urothelial markers GATA3 and CK7, while prostate-specific markers PSA and AR were negative, confirming the diagnosis of primary high-grade urothelial carcinoma of the prostate. This case indicates that a negative PSMA PET/CT scan may serve as an important diagnostic clue in distinguishing non-adenocarcinomatous prostate malignancies.
引用
- Shen R, Shen L, Xing Y, et al. Primary High-grade Urothelial Carcinoma of the Prostate With Negative 18F-PSMA PET/CT Imaging. Clin Nucl Med. 2026. PMID: 41955233. doi:10.1097/RLU.0000000000006468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。